Evidence map›Paper›PMID 30426067›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2018

The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress.

Michael A Irvine, Andrew Scholey, Rebecca King, Rachel Gillings, David Vauzour, Stephen J Demichele, Tapas Das, Keith A Wesnes, Brad P Sutton, Aedin Cassidy and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02525198 (A Randomised Controlled Trial in 'At Risk' Humans Investigating the Cognitive Benefits of a Combined Flavonoid/Fatty Acid Intervention and Underlying Mechanisms of Action), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02525198 nacompletednot on this map

A Randomised Controlled Trial in 'At Risk' Humans Investigating the Cognitive Benefits of a Combined Flavonoid/Fatty Acid Intervention and Underlying Mechanisms of Action: The COGNITIVE AGING NUTRITION and NEUROGENESIS (CANN) Trial

TypeinterventionalSponsorUniversity of East AngliaRan2015 to 2018Enrolled259ConditionsMild Cognitive Impairment, Subjective Memory ImpairmentArmsfatty acid/flavonoid blend, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Gut microbes · 2025
    Article
  5. Article
  6. Article
  7. Chronic Consumption of Cranberries (Frontiers in nutrition · 2022
    Article
  8. Brain communications · 2021
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Michael A IrvineDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.
Andrew ScholeyCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia.
Rebecca KingCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia.
Rachel GillingsDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.
David VauzourDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.
Stephen J DemicheleStrategic Research and Development, Abbott Nutrition, Abbott Laboratories, Columbus, OH, USA.
Tapas DasStrategic Research and Development, Abbott Nutrition, Abbott Laboratories, Columbus, OH, USA.
Keith A WesnesUniversity of Exeter Medical School, St Luke's Campus, Exeter, UK.
Brad P SuttonBeckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbane, IL, USA.
Aedin CassidyDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.
Andrew PipingasCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia.
John F PotterDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.
Glyn JohnsonDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.
David WhiteCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia.
Ryan LarsenStrategic Research and Development, Abbott Nutrition, Abbott Laboratories, Columbus, OH, USA.
Neal J CohenStrategic Research and Development, Abbott Nutrition, Abbott Laboratories, Columbus, OH, USA.
Anne-Marie MinihaneDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults.

methodsIn a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive measures, brain atrophy and blood flow (assessed by magnetic resonance imaging), vascular function, circulating biomarkers of cardiovascular and cognitive health, gut microflora, red blood cell fatty acid status, and urine flavan-3-ol metabolites.

resultsScreening began in 2015, with all baseline visits completed in March 2017. The intervention was finished in March 2018. DISCUSSION: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could ultimately contribute to a reduced population burden of dementia. CLINICALTRIALSGOV: NCT02525198.

Indexed as

Cocoa flavan-3-olsCognitionDementiaDocosahexaenoic acidEicosapentaenoic acidHippocampusMagnetic resonance imagingMild cognitive impairmentSubjective memory impairment

Identifiers

PMID30426067
PMCPMC6222033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.